Brief: Bausch + Lomb Advancing Two First-In-Class Eye Health Therapies Based On Trial Results
24/08/2026 21:47
BRIEF-Bausch + Lomb Advancing Two First-In-Class Eye Health Therapies Based On Trial Results Aug 24 (Reuters) - Bausch + Lomb Corp BLCO.TO:
BAUSCH + LOMB ADVANCING TWO FIRST-IN-CLASS EYE HEALTH THERAPIES BASED ON TRIAL RESULTS
BAUSCH + LOMB - DUAL-ACTION EYE DROP SHOWS SIGNIFICANT REDUCTION IN TCFS AT DAY 15 VERSUS LIFITEGRAST
BAUSCH + LOMB - TO ADVANCE DUAL-ACTION EYE DROP INTO PHASE 3
BAUSCH + LOMB - BL1332 MEETS PRIMARY ENDPOINT IN PHASE 1B WITH SIGNIFICANT PAIN REDUCTION
BAUSCH + LOMB: DUAL-ACTION EYE DROP STUDY FAILS PRIMARY ENDPOINT VERSUS LIFITEGRAST ALONE AT DAY 29
BAUSCH + LOMB - COMBINED POTENTIAL PEAK SALES FOR BOTH THERAPIES EXCEED $2 BILLION
BAUSCH + LOMB: PHASE 2 RESULTS FOR BL1332 OCULAR PAIN THERAPY EXPECTED IN COMING MONTHS
Source text: ID:nBw54QKqwa
Further company coverage: BLCO.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bausch + Lomb
See all newsBausch + Lomb CEO Saunders departs, Chairman Appio named interim chief (updated)
Brief: Bausch + Lomb And Bausch Health Announce Appointment Of Thomas J. Appio As Interim Bausch + Lomb CEO, Expect To Raise Full-Year 2026 Guidance
Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief
Brief: US FDA sent warning letter to Bausch & Lomb on September 4
Brief: Bausch + Lomb Announces European CE Mark Approval Of Seelyra™ Femtosecond Laser